Filing Flows › Impact Biomedical (IBO) › Q3 2026 › vs Q2 2026
Impact Biomedical (IBO) Q3 2026 vs Q2 2026 (quarter over quarter)
Impact Biomedical's revenue rose $18K (+600%) from $3K in Q2 2026 to $21K in Q3 2026.
Impact Biomedical, Q3 2026: revenue $21K (+17% year over year), net loss $644K, operating cash flow $11K. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $21K | $3K | $18K | +600% |
| Other income, net | $4K | $2K | $2K | +100% |
| Net loss | $644K | $700K | −$56K | -8% |
| Costs & expenses | $669K | $705K | −$36K | -5% |
| Operating costs | $669K | $705K | −$36K | -5% |
| Cost of revenue | $6K | $1K | $5K | +500% |
| Research & development | $35K | $76K | −$41K | -54% |
| SG&A | $156K | $167K | −$11K | -7% |
| Other operating costs | $472K | $461K | $11K | +2% |
| Operating cash sources | $655K | $1.2M | −$515K | -44% |
| Depreciation & amortization | $284K | $284K | $0 | 0% |
| Working capital & other | $371K | $886K | −$515K | -58% |
| Net loss absorbed | $644K | $700K | −$56K | -8% |
| Operating cash flow | $11K | $470K | −$459K | -98% |
Questions
How much did Impact Biomedical's revenue grow quarter over quarter in Q3 2026?
Impact Biomedical's revenue rose $18K (+600%) from $3K in Q2 2026 to $21K in Q3 2026.